Tag: well

LUXEMBOURG, Aug. 10, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a decentralized financial operating system integrating programmable PoY (Proof of Yield) rewards, AI-powered smart contracts, decentralized identity, and a hybrid PoW plus PoS consensus, has announced the latest developments in its Stage 4 presale. The presale is currently priced at $4, with a planned launch price of $15, offering Stage 4 participants an APY of 106%.

ROAD TOWN, British Virgin Islands, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Ozak AI’s growth is showing no signs of slowing down, with the project now surpassing $1.6 million in total funds raised. Over 90 million $OZ tokens have already been sold out, demonstrating the surging demand from crypto investors keen to gain exposure to one of the most talked-about AI-driven crypto initiatives this year.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals

GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against CTO Realty Growth, Inc. (“CTO” or the “Company”) (NYSE: CTO) and certain officers.   The class action, filed in the United States District Court for the Middle District of Florida, and docketed under 25-cv-01516, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CTO securities between February 18, 2021 and June 24, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.